Please login to the form below

Not currently logged in
Email:
Password:

West reveals 1m share repurchase programme

US-based West Pharmaceutical Services, a manufacturer of closure systems and syringe components for use with injectable drugs, has said that its board has approved a share repurchase programme of up to one million shares of its common stock.

US-based West Pharmaceutical Services, a manufacturer of closure systems and syringe components for use with injectable drugs, has said that its board has approved a share repurchase programme of up to one million shares of its common stock.

The programme will go into effect immediately and allow the company to repurchase its shares on the open market or in privately negotiated transactions in accordance with the Securities and Exchange Commission. The programme should complete within one year.

Donald E Morel Jr, West's chairman and CEO , said: "The current valuation of West stock makes repurchases a solid investment and represents an attractive opportunity to enhance long-term shareholder value."

"The board's action reflects our great confidence in our long-term business plan, the strength of our balance sheet and strong operating cash flow. From a financial perspective, we are well-positioned to fund our expansion activities, invest in growth opportunities through our Innovation Programmes, pay a dividend and buy back shares, which taken together, will create value for our shareholders," added Morel.

10th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics